This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases and identify the risk factors associated with severe COVID-19 pneumonia . This was a retrospective study in a tertiary care center conducted through the period between March 2020 and November 2020 and included all adult patients with rheumatic diseases who tested positive on the COVID-19 polymerase chain reaction (PCR) test . We assessed the patients' demographic data, history of rheumatic disease, COVID-19 symptoms and experimental treatment, if any, their disease course, and outcome . In all , 47 patients were included, and most were females . The commonest rheumatic diseases were rheumatoid arthritis (53.2 %), followed by systemic lupus erythematosus (21.3 %), and psoriatic arthritis (10.6 %). Methotrexate and hydroxychloroquine were the most commonly used disease-modifying anti-rheumatic drugs in 36.1% and 25.5%, respectively . Out of 47 patients , 48.9% required hospitalization with a median hospital stay of 7 days . Severe COVID-19 pneumonia, defined as clinical signs of pneumonia plus one of the following: respiratory rate> 30 bpm, severe respiratory distress, or oxygen saturation <90% in room air was observed in 19.1% of the patients, and one patient died . We found that elderly patients with a mean age of 65.3 years were more likely to develop severe COVID-19 pneumonia and that was statistically significant . Our study showed that elderly patients with a mean age of 65 years and having rheumatic diseases had an increased risk of hospital admission and development of severe COVID-19 pneumonia.